Karen Kelly, M.D.

Clinical/Research Interests

Dr. Kelly is an internationally recognized lung cancer expert dedicated to providing enhanced cancer care through cutting-edge clinical trials. Her research spans the spectrum of this disease from prevention to treatment. Dr. Kelly has been at the forefront in the development of numerous clinical trials evaluating anticancer agents to treat lung cancer and novel compounds to prevent lung cancer. She is also involved in developing biomarkers for screening and early detection of lung cancer.

Title:

Associate Director for Clinical Research, Phase I Clinical Director, Professor of Medicine

Specialty:

Hematology and Oncology, Cancer, Internal Medicine

Center/Program Affiliation:

UC Davis Comprehensive Cancer Center

Address:

UC Davis Comprehensive Cancer Center
4501 X St., Suite 3016
Sacramento, CA 95817

Phone:

916-734-5959

Education:

University of Kansas School of Medicine
Kansas City, Kansas
M.D. 1984

Emporia State University
Emporia, Kansas
B.S. 1978

Internships:

University of Colorado Health Sciences Center
Denver, Colorado
1985

Residency:

University of Colorado Health Sciences Center
Denver, Colorado
1987

Fellowships:

University of Colorado Health Sciences Center
Denver, Colorado
1990

Board Certifications:

American Board of Internal Medicine, Medical Oncology, 1993
American Board of Internal Medicine, 1987

Professional Memberships:

American Association for Canter Research (AACR)
International Association for the Study of Lung Cancer (IASLC)
Southwest Oncology Group (SWOG)

Honors and Awards:

Kansas City Business Journal Best Doctors in Kansas City, 2010
America's Top Doctors, 2008-2010
America's Top Doctors for Cancer, 2005-2010
Best Doctors, 2003-2011
Glasgow Memorial Achievement Citation for Scholastic Achievement, 1984
Alpha Omega Alpha Honor Medical Society, 1983

Select Recent Publications:

Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA Jr, Geraci MW, Miller YE. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila). 2011 Jun;4(6):793-802.

Huang CH, Williamson SK, Van Veldhuizen PJ, Hsueh CT, Allen A, Tawfik O, Wick J, Smith H, Uypeckcuat AM, Mayo M, Kelly K. Potential Role of Platelet Derived Growth Factor Receptor inhibition using Imatinib in Combination with Docetaxel in the treatment of recurrent Non-Small cell Lung Cancer. J Thorac Oncol. 2011 Feb;6(2):372-7.

Blanchard EM, Moon J, Hesketh PJ, Kelly K, Wozniak AJ, Crowley J, Gandara D. Comparison of Platinum-Based Chemotherapy in Patients Older and Younger Than 70 Years: An Analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol. 6:115-20, 2011.

Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley, Gandara DR. Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Study 0342. J Clin Oncol. 28:4747-54, 2010.

Kelly K, Kittelson J, Bunn PA Jr., Blatchford P, Keith R, Franklin W, Hirsch F, Lewis MT, Jackson MK, Klein C. A Randomized Phase II Chemoprevention Trial of 13-cis Retinoic Acid +/- Alpha Tocopherol or Observation in Subjects at High Risk for Lung Cancer. Cancer Prev Res. 2:440-9, 2009.

Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung, YC, Lau DH, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26(15): 2450-6, 2008.

To see if Karen Kelly is accepting new patients, or for assistance finding a UC Davis doctor, please call (800) 2-UC DAVIS.